Marni B. Siegel - Concepedia

Author

Marni B. Siegel

University of North Carolina at Chapel Hill

Also Known As

Anders, Carey, B. Siegel, Marni, Marni B Siegel, Marni B. Siegel, Marni Siegel, Mose, Lisle E., Shetty, Amol C., Siegel, Marni, Siegel, Marni B., Superfine, Richard

Publications

Citations

H-Index

Concepts

All Affiliations

University of North Carolina at Chapel Hill UNC Lineberger Comprehensive Cancer Center Translational Genomics Research Institute Segeberger Kliniken Fred Hutch Cancer Center

About

Marni B. Siegel is an author at University of North Carolina at Chapel Hill specializing in medicine, cell biology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	433
2	Cell Biology	4	4	406
3	Engineering	1	1	191
4	Health Sciences	1	1	24
5	Immunology	1	1	24

Marni B. Siegel

Publications

Citations

H-Index

Page 1

	Year	Citations
Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer Marni B. Siegel, Xiaping He, Katherine A. Hoadley, Journal of Clinical Investigation Breast Cancer MetastasisBreast OncologyEngineeringPathologyGenetic Drivers	2018	191
HIF1α and HIF2α independently activate SRC to promote melanoma metastases Sara C. Hanna, Bhavani Krishnan, Sean T. Bailey, Journal of Clinical Investigation Cancer ResearchTranscriptional RegulationOncologyMelanoma MetastasesMedicine	2013	144
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation David P. Kodack, Vasileios Askoxylakis, Gino B. Ferraro, Science Translational Medicine	2017	108
Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases Katherine A. Hoadley, Marni B. Siegel, Krishna Kanchi, PLoS Medicine	2016	105
Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i> -Mutated and <i>BRCA</i> –Wild-Type Triple-Negative Breast Cancer Olga Karginova, Marni B. Siegel, Amanda E.D. Van Swearingen, Molecular Cancer Therapeutics	2015	66
Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma Robert S. McNeill, Demitra A. Canoutas, Timothy J. Stuhlmiller, Neuro-Oncology	2017	60
Policy implications for familial searching Joyce Kim, Danny Mammo, Marni B. Siegel Investigative Genetics	2011	58
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases Amanda E.D. Van Swearingen, Marni B. Siegel, Allison M. Deal, Breast Cancer Research and Treatment Lccc 1025Breast OncologyMedicinePathologyPhase Ii Study	2018	47
Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC Xiaobei Zhao, Anyou Wang, Vonn Walter, PLoS ONE	2015	41
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer Amanda E.D. Van Swearingen, Maria J. Sambade, Marni B. Siegel, Neuro-Oncology	2017	40

Page 1